Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar

Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet